Literature DB >> 10228291

Is cyclic vomiting syndrome related to migraine?

B U Li1, R D Murray, L A Heitlinger, J L Robbins, J R Hayes.   

Abstract

OBJECTIVE: To examine the overlap between cyclic vomiting syndrome (CVS) and migraine by comparing 2 subsets of children with migraine-associated and non-migraine-associated CVS.
METHODS: We studied all children <18 years of age who met the consensus criteria for CVS after presentation to our pediatric gastroenterology service from 1986 to 1998. The clinical patterns and responses to treatment were obtained from a combination of chart reviews and structured interviews.
RESULTS: Among 214 children identified as having CVS, 82% were classified as having migraine-associated CVS based on 1 of 2 criteria either a family history of migraines or subsequent development of migraine headaches. Compared with the non-migraine CVS subgroup, the migraine subset had milder episodes (20.7 27.3 SD vs 39.5 66.5 emeses/episode, P =.006); more symptoms of abdominal pain (83% vs 66%), headache (41% vs 24%), social withdrawal (40% vs 22%), photophobia (36% vs 16%, all P <.05); more frequent triggering events (70% vs 49%, P =.013) including psychologic stress (39% vs 22%), physical exhaustion (23% vs 3%), and motion sickness (10% vs 0%); and a higher positive response rate to anti-migraine therapy (79% vs 36%, P =.002).
CONCLUSIONS: The majority of children with CVS were subclassified as having migraine-associated CVS. The migraine-associated subgroup had less severe vomiting, manifested symptoms typical of migraine headaches, and had higher response rates to anti-migraine therapy. These findings strengthen the relationship between migraine and CVS.

Entities:  

Mesh:

Year:  1999        PMID: 10228291     DOI: 10.1016/s0022-3476(99)70242-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  42 in total

1.  A case of cyclic vomiting syndrome responding to gonadotropin-releasing hormone analogue.

Authors:  Young Kook Shin; Joong Goo Kwon; Ka Young Kim; Jae Bum Park; Seok Jae Han; Jong Woon Cheon; Eun Young Kim; Ho Gak Kim; Tae Sung Lee; Kyung Sik Park; Kyoung Sook Won
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

2.  Cyclic Vomiting Syndrome.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-10

3.  Cyclic vomiting syndrome and functional vomiting in adults: association with cannabinoid use in males.

Authors:  R S Choung; G R Locke; R M Lee; C D Schleck; A R Zinsmeister; N J Talley
Journal:  Neurogastroenterol Motil       Date:  2011-09-27       Impact factor: 3.598

Review 4.  Diagnosing migraine in the pediatric population.

Authors:  Paul Winner; Andrew D Hershey
Journal:  Curr Pain Headache Rep       Date:  2006-10

Review 5.  Childhood periodic syndromes and migraine.

Authors:  Paul Winner
Journal:  Curr Pain Headache Rep       Date:  2005-06

6.  Prophylactic Therapy of Cyclic Vomiting Syndrome in Children: Comparison of Amitriptyline and Cyproheptadine: A Randomized Clinical Trial.

Authors:  Negin Badihian; Hossein Saneian; Shervin Badihian; Omid Yaghini
Journal:  Am J Gastroenterol       Date:  2017-07-18       Impact factor: 10.864

Review 7.  What the Gut Can Teach Us About Migraine.

Authors:  Nada Hindiyeh; Sheena K Aurora
Journal:  Curr Pain Headache Rep       Date:  2015-07

Review 8.  Treating children's cyclic vomiting.

Authors:  Shirley Chow; Ran D Goldman
Journal:  Can Fam Physician       Date:  2007-03       Impact factor: 3.275

9.  A comparison of dysautonomias comorbid with cyclic vomiting syndrome and with migraine.

Authors:  Gisela Chelimsky; Shruti Madan; Amer Alshekhlee; Elizabeth Heller; Kevin McNeeley; Thomas Chelimsky
Journal:  Gastroenterol Res Pract       Date:  2010-01-06       Impact factor: 2.260

10.  Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study.

Authors:  Richard G Boles; Mary R Lovett-Barr; Amy Preston; B Uk Li; Kathleen Adams
Journal:  BMC Neurol       Date:  2010-01-28       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.